The 21st century handbook of clinical Ovarian cancer

The 21st Century Handbook of Clinical Ovarian Cancer

Volumn , Issue , 2015, Pages 1-200

  Tewari, Krishnansu S ^a   Monk, Bradley J ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944031220     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-3-319-08066-6     Document Type: Book

References (244)

1. Tewari KS. Advanced cytoreductive surgery workshop report. Int J Gynecol C Cancer. 2012;22:1604-1610.
2. Clay C. Observations on ovariotomy. Statistical and practical. Transactions of the Obstetrics Society of London. 1863;5:58-74.
3. Bryant T. On Ovariotomy (Clinical Surgery, Part Vii). London: John Churchill & Sons; 1867.
4. Spencer HR. The history of ovariotomy. Proc R Soc Med. 1934;27:1437-1444.
5. Houstoun R. An account of a dropsy in the left ovary of a woman, aged 58, cured by a large incision made in the side of the abdomen. Transactions of the Royal Society.1724;xxxiii:2-4.
6. Mackinlay CJ. Who is Houstoun? A biography of Robert Houstoun M.D., F.R.S. 1678-1734. J Obstet Gynaecol Br Commonw. 1973;80:193-200.
7. Hunter W. On cellular tissue. The history of an emphysema. Medical Observations and Inquires. 1757;2.
8. McDowell E. Three cases of extirpation of diseased ovaria. Eclectic Repertory Anal Rev. 1817;7:242-244.
9. Horn L, Johnson DH. Ephraim McDowell, the first ovariotomy, and the birth of abdominal surgery. J Clin Oncol. 2010;28:1262-1268.
10. Benigno BB. Ephraim McDowell and Jane Todd Crawford: The bicentennial of a surgical masterpiece. Obstet Gynecol. 2009;113:1141-1144.
11. U.S. National Library of Medicine. Engravings of the bones, muscles, and joints, illustrating the first volume of the Anatomy of the Human Body. 2d ed. www.nlm.nih.gov/dreamanatomy/da_g_II-B-6.html. Last accessed November 17, 2014.
12. U.S. National Library of Medicine. Ephraim McDowell from the Painting by Davenport. ihm.nlm.nih.gov/luna/servlet/detail/NLMNLM~1~1~101422368~193549:Ephr aim-McDowell-From-the-painting-?sort=Title%2CSubject_MeSH_Term%2CCreator_ Person%2CCreator_Organization&qvq=q:ephraim+mcdowell;sort:Title, Subject_MeSH_ Term, Creator_Person, Creator_Organization;lc:NLMNLM~1~1&mi=2&trs=8. Last accessed November 17, 2014.
13. Bowra JM. Making a man, a great man: Ephraim McDowell, ovariotomy and history. eprints. qut.edu.au/3454/1/3454.pdf. Last accessed November 17, 2014.
14. Stanley B. Burns, MD and the Burns Archive. Jane Todd Crawford, 1809. www.burnsarchive. com. Accessed November 17, 2014.
15. Tait L. The Pathology and Treatment of Disease of the Ovaries. 4th Edn. New York, NY: William Wood & Co; 1983.
16. National Library of Medicine. The Late Lawson Tait, FRCS, End and Edin. 1980s. ihm.nlm.nih. gov/luna/servlet/view/search?q=B024811. Last accesssed November 17, 2014.
17. Meigs JV. Tumors of the Female Pelvic Organs. New York, NY: MacMillan; 1934.
18. Countway Library of Medicine. Joe Vincent Meigs (1892-1963). ihm.nlm.nih.gov/luna/servlet/detail/NLMNLM~1~1~101423500~184140:-Joe-V--Meigs--Photo-by-Fabian-Bach?printerFriendly=1. Last accessed November 17, 2014.
19. Lynch F. A clinical review of 110 cases of ovarian cancer. Am J Obst Gynecol. 1936;32:753-772.
20. Pemberton FA. Carcinoma of the ovary. Am J Obstet Gynecol. 1940;40:751-763.
21. Munell EW. The changing prognosis and treatment in cancer of the ovary. Am J Obstet Gynecol. 1968;100:790-805.
22. Brunschwig A. Complete excision of pelvic viscera for advanced carcinoma. A one-stage abdominoperineal operation with end colostomy and bilateral ureteral implantation into the colon above the colostomy. Cancer. 1948;1:177-183.
23. Barber HR, Brunschwig A. Pelvic exenteration for locally advanced and recurrent ovarian cancer. Review of 22 cases. Surgery. 1965;58:935-937.
24. Hudson CN. A radical operation for fixed ovarian tumours. J Obstet Gynaecol Br Commonw. 1968;75:1155-1160.
25. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
26. Magrath IT, Lwanga S, Carswell W, Harrison N. Surgical reduction of tumour bulk in management of abdominal Burkitt's lymphoma. Br Med J. 1974;2:308-312.
27. Griffiths CT, Fuller AF. Intensive surgical and chemotherapeutic management of advanced ovarian cancer. Surg Clin North Am. 1978;58:131-142.
28. Hunter RW, Alexander ND, Soutter WP. Meta-analysis of surgery in advanced ovarian carcinoma: Is maximum cytoreductive surgery an independent determinant of prognosis? Am J Obstet Gynecol. 1992;166:504-511.
29. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol. 2002;20:1248-1259.
30. Eisenkop SM, Friedman RL, Wang HJ. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: A prospective study. Gynecol Oncol. 1998;69:103-108.
31. Eisenkop SM, Spirtos NM. Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol. 2001;83:435-441.
32. Chi DS, Abu-Rustum NR, Sonoda Y, et al. The benefit of video-assisted thoracoscopic surgery before planned abdominal exploration in patients with suspected advanced ovarian cancer and moderate to large pleural effusions. Gynecol Oncol. 2004;94:301-311.
33. Sugarbaker PH. Complete parietal and visceral peritonectomy of the pelvis for advanced primary and recurrent ovarian cancer. Cancer Treat Res. 1996;81:75-87.
34. Cliby W, Dowdy S, Feitoza SS, et al. Diaphragm resection for ovarian cancer: Technique and short-term complications. Gynecol Oncol. 2004;94:655-660.
35. Chi DS, Temkin SM, Abu-Rustum NR, et al. Major hepatectomy at interval debulking for stage IV ovarian carcinoma: A case report. Gynecol Oncol. 2002;87:138-142.
36. Song YJ, Lim MC, Kang S, et al. Extended cytoreduction of tumor at the porta hepatis by an interdisciplinary team approach in patients with epithelial ovarian cancer. Gynecol Oncol. 2011;121:253-257.
37. Deppe G, Abella EA, Skogerson K, Dumitru I. The rare indication for splenectomy as part of cytoreductive surgery in ovarian cancer. Gynecol Oncol. 1983;16:282-287.
38. Keohe SM, Eisenhauer EL, Chi DS. Upper abdominal surgical procedures: Liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy. Gynecol Oncol. 2008;111(2 Suppl):S51-S55.
39. Eisenhauer EL, Abu-Rustum NR, Sonada Y, et al. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer. Gynecol Oncol. 2006;103:1083-1090.
40. Uildririm Y, Sanci M. The feasibility and morbidity of distal pancreatectomy in extensive cytoreductive surgery for advanced epithelial ovarian cancer. Arch Gynecol Obstet. 2005;272:31-34.
41. Wang D, Lippar SJ. Cellular processing of platinum anticancer drugs. Nature Reviews Drug Discovery. 2005;4:307-320.
42. Milne M, Fletcher GL. Pacific (western) yew. metchosinmarine.ca/metchosin/trees/pacificyew/pacificyew.htm. Last accessed November 17, 2014.
43. van Amerongen, Berns A. TXR1-mediated thrombospondin repression: a novel mechanism of resistance to taxanes? Genes Dev. 2006;20:1975-1981.
44. Makino K. Drug delivery system. In: Ohshima H, ed. Electrical Phenomena at Interfaces and Biofaces: Fundamentals and Applications in Nano-, Bio-, and Environmental Sciences. Hoboken, New Jersey: John Wiley & Sons, Inc; 2012;709-723.
45. Ueno H, Kiyosawa K, Kaniwa N. Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer. 2007;97:145-151.
46. ScienceNet. blog.sciencenet.cn/blog-212210-666757.html. Last accessed November 17, 2014.
47. Griffiths CT. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr. 1975;42:101-104.
48. Young RC, Decker DG, Wharton JT, et al. Staging laparotomy in early ovarian cancer. JAMA. 1983;250:3072-3076.
49. Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: A trial of the Gynecologic Oncology Group. J Clin Oncol. 1994;12:701-706.
50. US National Archives and Records Administration. President Richard Nixon. www.archives. gov/presidential-libraries/events/centennials/nixon/. Last accessed November 17, 2014.
51. National Human Genome Research Institute: National Institute of Health. www.genome.gov/. Last accessed November 17, 2014.
52. American Cancer Society. Fight cancer sword. images.agoramedia.com/everydayhealth/gcms/Fight-Cancer-Sword-1928-pg-full.jpg. Last accessed November 17, 2014.
53. FDA News Release. FDA approves Lynparza to treat advanced ovarian cancer. First LDT companion diagnostic test also approved to identify appropriate patients. December 19, 2014. www.fda.gov. Last accessed January 17, 2015.
54. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.
55. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomized phase 2 trial. Lancet Oncol. 2014;15:852-861.
56. Kaufman B, Shapira-Frommer R, Schmutzler RK, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2014; doi: 10.1200/JCO.2014.56.2728 [Epub ahead of print].
57. American Cancer Society. Cancer Facts and Figures 2014. Atlanta, Ga: American Cancer Society, 2014. www.cancer.org/acs/groups/content/@research/documents/webcontent/acspc-042151.pdf. Last accessed November 17, 2014.
58. Eisenhauer EL, Salani R, Copeland LJ. Epithelial ovarian cancer, In: Clinical Gynecologic Oncology. 8th edn. DiSaia PJ, Creasman WT, eds. Philadelphia, PA: Elsevier Saunders; 2012:285-288.
59. Howlader N, Noone AM, Krapcho M, et al. eds. SEER Cancer Statistics Review, 1975-2011. Bethesda, MD: National Cancer Institute; 2012. seer.cancer.gov/csr/1975_2011/. Last accessed November 17, 2014.
60. Scully R, Sobin L. Histological Typing of Ovarian Tumours. Volume 9. New York, NY: Springer Berlin; 1999.
61. World Health Organization histological classification 2013. www.seap.es/documents/228448/528821/01_Prat.pdf. Last accessed November 17, 2014.
62. Karst AM, Drapkin R. Ovarian cancer pathogenesis: a model in evolution. J Oncol. 2010;2010:932371.
63. Johnson PA, Giles JR. The hen as a model of ovarian cancer. Nat Rev Cancer. 2013;13:432-436.
64. Herrinton LJ, Stanford JL, Schwartz SM, Weiss NS. Ovarian cancer incidence among Asian migrants to the United States and their descendants. J Natl Cancer Inst. 1994;86:1336-1339.
65. Prat J. FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet. 2014;124:1-5.
66. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer Statistics Review 1975-2011. seer.cancer.gov/csr/1975_2011/browse_csr.php?sectionSEL=21 &pageSEL=sect_21_table.08.html. Last accessed November 17, 2014.
67. Edwards BK, Noone AM, Mariotto AB, et al. Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer. 2014;120:1290-1314.
68. Centers for Disease Control and Prevention and the National Institute of Child Health and Human Development. The reduction in risk of ovarian cancer associated with oralcontraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med. 1987;316:650-655.
69. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst. 2002;94:32-38.
70. Greer JB, Modugno F, Allen GO, Ness RB. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.
71. Berek JS, Chalas E, Edelson M, et al. Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. Obstet Gynecol. 2010;116:733-743.
72. Kurman RJ, Shih Ie-Ming. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443.
73. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185-192.
74. Welsch PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705-713.
75. Green MH, Piedmonte M, Alberts D, et al. A prospective study of risk-reducing salpingooophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. Cancer Epidemiol Biomarkers Prev. 2008;17:594-604.
76. Mai PL, Sherman ME, Piedmonte M, et al. Pathologic findings at risk-reducing salpingooophorectomy among women at increased ovarian cancer risk: results from GOG-199. J Clin Oncol. 2012;30 (abstr 1519).
77. Bast RC Jr, Klug TL, St John E, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med. 1983;309:883-887.
78. Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4:365-374.
79. Buys SS, Partridge E, Black A, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011;305:2295-2303.
80. Moore LE, Pfeiffer RM, Zhang Z, et al. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Cancer. 2012;118:91-100.
81. Partridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113:775-782.
82. McIntosh MW et al. Generating longitudinal screening algorithms using novel biomarkers for disease. Cancer Epidemiol Biomarkers Prev. 2002;11:159-166.
83. Lu KH, Skates S, Hernandez MA, et al. A 2-stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early-stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119:3454-3461.
84. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327-340.
85. Rosenthal AN, Fraser L, Manchanda R, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31:49-57.
86. Rosenthal N, Fraser L, Philpott S, et al. Final results of 4-monthly screening in the UK Familial Ovarian Cancer Screening Study (UKFOCSS Phase 2). J Clin Oncol. 2013;31(suppl;abstr 5507).
87. American College of Obstetricians and Gynecologists. ACOG Committee Opinion: Number 280, December 2002. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. Obstet Gynecol. 2002;100:1413-1416.
88. Zhu CS, Pinsky PF, Cramer DW, et al. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila). 2011;4:375-383.
89. Miller RW, Smith A, DeSimone COP, et al. Performance of the American College of Obstetricians and Gynecolgists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol. 2011;117:1-9.
90. Ueland FR, Desimone CP, Seamon LG, et al. Effectiveness of a multivariate index assayin the preoperative assessment of ovarian tumors. Obstet Gynecol. 2011;117:1289-1297.
91. Bristow RE, Smith A, Zhang Z, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecol Oncol. 2013;128:252-259.
92. Hellström I, Raycraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695-3700.
93. Moore RG, Brown AK, Miller C, et al. The use of multiple novel serum biomarkers for the detection of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2008;108;402-408.
94. Moore RG, McMeekin DC, Brown AK, et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40-46.
95. Moore RG, Miller C, Disilvestro P, et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstet Gynecol. 2011;118:280-288.
96. Coleman RL, Monk BJ, Sood AK, Herzog TJ. Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol. 2013;10:211-224.
97. Bristow RE, Chang J, Ziogas A, Anton-Culver H. Adherence to treatment guidelines for ovarian cancer as a measure of quality care. Obstet Gynecol. 2013;121:1226-1234.
98. Hasovits C, Clarke S. Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics. Clin Pharmacokinet. 2012;51:203-224.
99. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1-6.
100. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
101. Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374:1331-1338.
102. Katsumata N, Yasuda M, Isonishi S, et al. Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. Lancet Oncol. 2013;14:1020-1026.
103. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200.
104. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682-1691.
105. Vergote I, Topé CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943-953.
106. Kehoe S, Hook J, Nankivell M, et al. Chemotherapy or upfront surgery for newly diagnosed advanced ovarian cancer: results from the MRC CHORUS trial. J Clin Oncol. 2013;31:suppl; abstr 5500.
107. Bell J, Brady MF, Young RC, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;102:432-439.
108. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
109. Markman M, Liu PY, Wilczynski S, et al. Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. J Clin Oncol. 2003;21:2460-2465.
110. Markman M, Liu PY, Moon J, et al. Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete responses to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol Oncol. 2009;114:195-198.
111. National Cancer Institute. Paclitaxel or polyglutamate paclitaxel or observation in treating patients with stage III or stage IV ovarian epithelial or peritoneal cancer or fallopian tube cancer. www.cancer.gov/clinicaltrials/search/view?cdrid=422427&version=HealthProfessio nal. Last accessed November 17, 2014.
112. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003;361:2099-2106.
113. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107-3114.
114. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183-2193.
115. Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312-3322.
116. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699-4707.
117. Pujade-Lauraine E, Wagner U, Aavall-Lundgvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323-3329.
118. Miller DS, Blessing JA, Krasner CN, et al. Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group. J Clin Oncol. 2009;27:2686-2691.
119. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155-1163.
120. Coleman RL, Brade WE, McMeeking DS, et al. A phase II evaluation of nanoparticle, albuminbound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2011;122:111-115.
121. Ray-Coquard I, Weber B, Cretin J, et al. Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group. Br J Cancer. 2009;100:601-607.
122. Brewer CA, Blessing JA, Nagourney RA, et al. Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 2006;103:446-450.
123. Rose PG, Blessing JA, Mayer AR, Homesley HD. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 1998;16:405-410.
124. Durante F. Nesso fisio-pathologico tra la struttura dei nei materni e la genesi di alcuni tumori maligni. Arch Memor Observ Chir Pract. 1874;11:217-226.
125. Wicha MS, Liu S, Dontu G. Cancer stem cells: An old idea-a paradigm shift. Cancer Res. 2006;66:1883-1890.
126. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253-1261.
127. Brenton JD, Stingl J. Stem cells: anatomy of an ovarian cancer. Nature. 2013;495:183-184.
128. Curley MD, Garrett LA, Schorge JO, Foster R, Rueda BR. Evidence for cancer stem cells contributing to the pathogenesis of ovarian cancer. Front Biosci. 2011;16:368-392.
129. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature. 1979;278:261-263.
130. Reles A, Wen WH, Schmider A, et al. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res. 2001;7:2984-2997.
131. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet. 2006;7:21-33.
132. Jacobs IJ, Kohler MF, Wiseman RW, et al. Clonal origin of epithelial ovarian carcinoma: analysis by loss of heterozygosity, p53 mutation, and X-chromosome inactivation. J Natl Cancer Inst. 1992;84:1793-1798.
133. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077-3080.
134. Prathapam T, Aleshin A, Guan Y, Gray JW, Martin GS. p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs. J Biol Chem. 2010;285:32529-32538.
135. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250:1684-1689.
136. Bowcock AM, Anderson LA, Friedman LS, et al. THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21. Am J Hum Genet. 1993;52:718-722.
137. Simard J, Feunteun J, Lenoir G, et al. Genetic mapping of the breast-ovarian cancer syndrome to a small interval on chromosome 17q12-21: exclusion of candidate genes EDH17B2 and RARA. Hum Mol Genet. 1993;2:1193-1199.
138. Tonin P, Serova O, Simard J, et al. The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12-q21. Hum Mol Genet. 1994;3:1679-1682.
139. Smith SA, DiCioccio RA, Struewing JP, et al. Localisation of the breast-ovarian cancer susceptibility gene (BRCA1) on 17q12-21 to an interval of < or = 1 cM. Genes Chromosomes Cancer. 1994;10:71-76.
140. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088-2090.
141. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in common pathway of genome protection. Nat Rev Cancer. 2012;12:68-78.
142. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;2111:26-35.
143. Pool M. Mini case report: early serous carcinoma in fallopian tube in BRCA2 carrier. pathlabmed.typepad.com/surgical_pathology_and_la/2010/01/mini-case-report-earlyserous-carcinoma-in-fallopian-tube-in-brca2-carrier.html. Last accessed November 17, 2014.
144. Norquist BM, Garcia RL, Allison KH, et al. The molecular pathogenesis of hereditary ovarian carcinoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutations. Cancer. 2010;116:5261-5271.
145. Lonning PE, Bjornslett M, Knappskog S, et al. Effect of WBC BRCA1 promote methylation on ovarian cancer risk. J Clin Oncol. 2011;29(suppl):5029.
146. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
147. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-674.
148. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615.
149. Hampton OA, Hollander PD, Miller CA, et al. A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome. Genome Res. 2009;19:167-177.
150. Tewari KS, Mehta RS, Burger RA, et al. Conservation of in vitro drug resistance patterns in epithelial ovarian carcinoma. Gynecol Oncol. 2005;98:360-368.
151. Tewari KS, Kyshtoobayeva AS, Mehta RS, et al. Biomarker conservation in primary and metastatic epithelial ovarian cancer. Gynecol Oncol. 2000;78:130-136.
152. Schrag D, Garewal HS, Burstein HJ, et al. American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004;22:3631-3638.
153. Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011;29:3328-3330.
154. Rutherford T, Orr J Jr, Grendys E Jr, et al. A prospective study evaluating the clinical relevance of a chemoresponse assay for treatment of patients with persistent or recurrent ovarian cancer. Gynecol Oncol. 2013;131:362-367.
155. Ferrara N, Carver-Moore K, Chen H, et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature. 1996;380:439-442.
156. Malpica A, Deavers MR, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28:496-504.
157. Ide AGBN, Warren SL. Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transparent ear chamber. Am J Roentgenol. l939;42:891-899.
158. Folkman J ME, Abernathy C, Williams G. Isolation of a tumor factor responsible for angiogenesis. J Exp Med. l1971;133:275-288.
159. Ferrara N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med (Berl). 1999;77:527-543.
160. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature. 1993;362:841-844.
161. Borgstrom P, Hillan KJ, Sriramarao P, Ferrara N. Complete inhibition of angiogenesis and growth of microtumors by anti-vascular endothelial growth factor neutralizing antibody: novel concepts of angiostatic therapy from intravital videomicroscopy. Cancer Res. 1996;56:4032-4039.
162. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242-248.
163. Rusnati M, Presta M. Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des. 2007;13:2025-2044.
164. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J. 2004;18:338-340.
165. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005;438:967-974.
166. Eskander RN, Tewari KS. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol Oncol. 2014;132:496-505.
167. Gourley C, Michie CO, Keating KE, et al. Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens. J Clin Oncol. 2011;29:(suppl; abstr 5000).
168. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J. 1999;342:249-268.
169. Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473-2483.
170. Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484-2496.
171. Oza AM, Perren TJ, Swart AM, et al. ICON7: Final overall survival results in the GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer. Eur J Cancer. 2013;49(Suppl3):LBA6.
172. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized, double-blind, placebocontrolled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30:2039-2045.
173. Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1302-1308.
174. Du Bois A, Floquet A, Kim JW, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014 Sep 15. [Epub ahead of print].
175. Ledermann JA, Perren TJ, Raja FA, et al. Randomised double-blind phase III trial of cediranib (AZD 2171) in relapsed platinum sensitive ovarian cancer: results of the ICON6 trial. Eur J Cancer. 2013;49:(suppl 3):abstr LBA10.
176. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30:362-371.
177. Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014;15:799-808.
178. Amgen. News Release Details. Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3 Trebananib TRINOVA-1 Trial In Patients With Recurrent Ovarian Cancer. www.amgen. com/media/media_pr_detail.jsp?year=2014&releaseID=1985448. Published November 4, 2014. Last accessed November 17, 2014.
179. Du Bois A, Kristensen G, Ray-Coquard I, et al. AGO-OVAR 12: a randomized placebo-controlled GCIG/ENGOT-intergroup phase III trial of standard frontline chemotherapy +/-nintedanib for advanced ovarian cancer. Int J Gynecol Cancer. 2013;23(suppl 1):abstr LBA1.
180. McKeage MJ, Baguley BC. Disrupting established tumor blood vessels. Cancer. 2010;116:1859-1871.
181. ThermaSolutions. Enhanced outcome with intraperitoneal hyperthermia. The ThermoChemTM HT System. www.thermasolutions.com/images/HT-1000_Brochure.pdf. Last accessed November 17, 2014.
182. Fagotti A, Constantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122:221-225.
183. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783-1791.
184. Endocyte. The future of precision medicine. www.endocyte.com. Last accessed November 17, 2014.
185. Naumann RW, Coleman RL, Burger RA, et al. PRECEDENT: a randomized phase II trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD) in combination versus PLD alone in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2013;31:4400-4406.
186. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361:123-134.
187. O'Shaughnessy J, Osborne C, Pippen M, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. J Clin Oncol. 2009;27:18s (suppl; abstr 3)
188. Audeh MW, Carmichael J, Penson RT, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet. 2010;376:245-251.
189. Gelmon KA, Tischkowitz M, Mackay H, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852-861.
190. Kaye SB, Lubinski J, Matulonis U, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012;30:372-379.
191. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012;366:1382-1392.
192. Oza AM, Cibula D, Oaknin A, et al. Olaparib plus paclitaxel plus carboplatin followed by olaparib maintenance treatment in patients with platinum-sensitive recurrent serous ovarian cancer: a randomized, open-label phase II study. J Clin Oncol. 2012;30:(suppl):abstr 5001.
193. Sandhu SK, Schelman WR, Wilding G, et al. The poly(ADP-ribose) polymersase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882-892.
194. Ihnen M, zu Eluenburg C, Kolarova T, et al. Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol Cancer Ther. 2013;12:1002-1015.
195. Farley J, Brady WE, Vathipadiekal V, et al. Selumetinib in women with recurrent low-grade serous cacinoma of the ovary or peritoneum: An open-label, single-arm, phase 2 study. Lancet Oncol. 2013;14:134-140.
196. Shih I-M, Wang T-L. Notch signaling, γ-secretase inhibitors, and cancer therapy. Cancer Res. 2007;67:1879-1882.
197. Yang G, Chang B, Yang F, et al. Aurora kinase A promotes ovarian tumorigenesis through dysregulation of the cell cycle and suppression of BRCA2. Coin Cancer Res. 2010;16:3171-3181.
198. Matulonis UA, Sharma S, Ghamande S, et al. Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or-refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012;127:63-69.
199. Goldman JW, Raju RN, Gordon GA, et al. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies. BMC Cancer. 2013;13:152-161.
200. Liu J, Barry WT, Birrer MJ, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014;15:1207-1214.
201. Monk BJ, Sill MW, Walker J, et al; Gynecologic Oncology Group. Bevacizumab with or without fosbretabulin tromethamine in patients with recurrent or persistent ovarian epithelial, fallopian tube, or peritoneal cavity cancer. Presented at: 15th Biennial Meeting of the International Gynecologic Cancer Society; November 8-11, 2014; Melbourne, Australia. Abstract OS02.
202. Brueseke TJ, Tewari KS. Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinoma. Clin Pharmacol. 2013;5:13-19.
203. Bristol Myers Squibb. Mechanism of action. https://www.hcp.yervoy.com/pages/mechanismof-action.aspx. Last accessed November 17, 2014.
204. Topalian SL, Brahmer JR, Hodi FS, et al. Anti-PD-1 (BMS-936558, MDX-1106) in patients with advanced solid tumors: Clinical activity, safety, and a potential biomarker for response. Slides presented at: 2012 ASCO Annual Meeting; June 1-June 5, 2013; Chicago, IL. Abstract CRA2509.
205. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
206. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122-133.
207. Cannon MJ, Goyne H, Stone PJ, Chiriva-internati M. Dendritic cell vaccination against ovarian cancer-tipping the Treg/TH17 balance to therapeutic advantage. Expert Opin Biol Ther. 2011;11:441-445.
208. Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer as a predictor of outcome following bevacizumab. J Clin Oncol. 2014;32:5s (suppl; abstr 5502).
209. Prat J. Ovarian carcinomas: five distinct disease with different origins, genetic alterations, and clinicopatholgoical features. Virchows Arch. 2012;460:238-249.
210. Farley J, Brady WE, Vathipadiekal V, et al. Better therapeutic trials in ovarian cancer. Lancet Oncol. 2013;14:134-140.
211. Zorn KK, Bonome T, Gangi L, et al. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005;11:6422-6430.
212. Romero I, Sun CC, Wong KK, et al. Low-grade serous carcinoma: new concepts and emerging therapies. Gynecol Oncol. 2013;130:660-666.
213. Schiavone MB, Herzog TJ, Lewin SN, et al. Natural history and outcome of mucinous carcinoma of the ovary. Am J Obstet Gynecol. 2011;205:480.e1-e8.
214. McAlpine JN, Wiegand KC, Vang R, et al. HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy. BMC Cancer. 2009;9:433.
215. Jones S, Wang TL, Shih Le M, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010;330:228-231.
216. Del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: A review of the literature. Gynecol Oncol. 2012;126:481-490.
217. Mackay HJ, Brady MF, Oza AM, et al. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer. J Gynecol Cancer. 2010;20:945-952.
218. Takakura S, Takano M, Takahashi F, et al. Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-lien chemotherapy for clear cell adenocarcinoma of the ovary: A JGOG study. Int J Gynecol Cancer. 2010;20:240-247.
219. Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363:1532-1543.
220. Low JJ, Ilancheran A, Ng JS. Malignant ovarian germ-cell tumors. Best Pract Res Clin Obstet Gynaecol. 2012;26:347-355.
221. Shah SP, Kobel M, Senz J, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360:2719-2729.
222. Jamieson S, Fuller PJ. Management of granulosa cell tumour of the ovary. Curr Opin Oncol. 2008;20:560-564.
223. Young RH. Sertoli-Leydig cell tumors of the ovary: Review with emphasis on historical aspects and unusual variants. Int J Gynecol Pathol. 1993;12:141-147.
224. Trillsch F, Ruetzel JD, Herwig U, et al. Surgical management and perioperative morbidity of patients with primary borderline ovarian tumor (BOT). J Ovarian Res. 2013;6:48.
225. Park JY, Kim DY, Suh DS, et al. Outcomes of fertility-sparing surgery for invasive epithelial ovarian cancer: Oncologic safety and reproductive outcomes. Gynecol Oncol. 2008;110:345-353.
226. Minig L, Otano L, Diaz-Padilla I, et al. Therapeutic management of epithelial ovarian cancer during pregnancy. Clin Transl Oncol. 2013;15:259-264.
227. Moore P (ed). The Developing Human. 6th edn. Philadelphia: Saunders; 1998.
228. McMahon JT, Hart WR. Ultrastructural analysis of small cell carcinomas of the ovary. Am J Clin Pathol. 1988;90:523-529.
229. Senekjian EK, Weiser PA, Talerman A, Herbst AL. Vinblastine, cisplatin, cyclophosphamide, bleomycin, doxorubicin, and etoposide in the treatment of small cell carcinoma of the ovary. Cancer. 1989;64:1183-1187.
230. Tewari K, Brewer C, Cappuccini F, et al. Advanced-stage small cell carcinoma of the ovary in pregnancy: Long-term survival after surgical debulking and multiagent chemotherapy. Gynecol Oncol. 1997;66:531-534.
231. Rana S, Warren BK, Yaada SD. Stage IIIC small cell carcinoma of the ovary: Survival with conservative surgery and chemotherapy. Obstet Gynecol. 2004;103;120-123.
232. Bradley RF, Stewart JH 4th, Russell GB. Pseudomyxoma peritonei of papendiceal origin: A clinicopathologic analysis of 101 patients uniformly treated at a single institution, with literature review. Am J Surg Pathol. 2006;30:551-559.
233. Chua TC, Moran BJ, Sugarbaker PH, et al. Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30:2449-2456.
234. Peng W, Hua RX, Jiang R, et al. Surgical treatment for patients with Krukenberg tumor of stomach origin: Clinical outcome and prognostic factors analysis. PLoS One. 2013;8:e68227.
235. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol. 2006;24:187-205.
236. Lee DG, Kim SH, Kim SY, et al. Evidence-based guidelines for empirical therapy of neutropenic fever in Korea. Korean J Intern Med. 2011;26:220-252.
237. Toth JA. Concepts in cancer pain management. US Pharm. 2009;34(Suppl):3-12.
238. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29:4189-4198.
239. Boothby LA, Howard C. Pharmacists' role in supportive care for cancer patients. US Pharm. 2005;1(Suppl):3-9.
240. Confino-Cohen R, Fishman A, Altaras M, Goldberg A. Successful carboplatin desensitization in patients with proven carboplatin allergy. Cancer. 2005;104:640-643.
241. Stubblefield MD, Burstein HJ, Burton AW, et al. NCCN Task Force Report: Management of neuropathy in cancer. J Natl Compr Canc Netw. 2009;7(Suppl5):S1-S28.
242. Van Poznak CH, Temin S, Yee GC, et al. American Society of Clincial Oncology Executive Summary of the Clinical Practice Guideline Update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol. 2011;29:1221-1227.
243. National Comprehensive Cancer Network. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology-Central Nervous System Cancers, Version 2.2014. www. NCCN.org. Last accessed November 17, 2014.
244. Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med. 1993;95:297-304.